id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-268347-xz6fptol	Kow, Chia Siang	Pharmacotherapeutic considerations for systemic rheumatic diseases amid the COVID-19 pandemic: more questions than answers	2020-08-16		.txt	text/plain	2665	132	33	It is not known for certain if there is an association between any pharmacological agent used for rheumatologic treatment, including biological and non-biological disease-modifying antirheumatic drugs (DMARDs), and an increased risk of COVID-19 acquisition or adverse outcomes from COVID-19, although these agents have been associated with an overall higher risk of infections. To illustrate, the aforementioned prospective case series [3] that included 86 patients from New York with confirmed or presumptive COVID-19 with concurrent immunemediated inflammatory disease reported no increased odds of COVID-19 hospitalization among those who were receiving biological agents or Janus kinase (JAK) inhibitors at baseline [adjusted odds ratio (OR) 0.85; 95% CI 0.71-1.02]. There are proven benefits for initiation or continuation of any pharmacological agents for the management of systemic rheumatic diseases, including treatment with conventional DMARDs and other immunosuppressive agents (e.g. hydroxychloroquine/chloroquine, sulfasalazine, methotrexate, leflunomide, tacrolimus, ciclosporin, mycophenolate mofetil and azathioprine), as well as biological DMARDs, such as abatacept, tocilizumab and JAK inhibitors (e.g. tofacitinib, baricitinib and upadacitinib).	./cache/cord-268347-xz6fptol.txt	./txt/cord-268347-xz6fptol.txt